Complete pathological response leads to improved survival in pancreatic cancer patients

Following neoadjuvant treatment with FOLFIRINOX for pancreatic adenocarcinoma, researchers observed a median overall survival of 177 months for patients achieving complete pathological response (cpr). Among 101 patients studied, overall survival rates after 1, 3, 5, and 10 years were 93%, 75%, 63%, and 51%, respectively. However, one-third experienced disease recurrence, with preoperative chemoradiotherapy correlated to worse outcomes, indicating it as a significant negative prognostic factor for both overall and recurrence-free survival.